Dermatology · Antifungal
The FDA's acceptance of Glenmark's ANDA for Ciclopirox signifies a potential shift in the competitive landscape of the antifungal market. This approval may lead to increased competition, impacting pricing and market share for existing Ciclopirox products.
Explore aggregated signals, assets, and competitive context for organizations linked to this signal.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/1/2026, 6:31:06 AM
Assessment confidence: 55% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.
The FDA's acceptance of Glenmark's ANDA for Ciclopirox signifies a potential shift in the competitive landscape of the antifungal market. This approval may lead to increased competition, impacting pricing and market share for existing Ciclopirox products. Regulatory context from FDA (FDA AP — CICLOPIROX (SUPPL)) supports the near-term read. Assessment grounded in 15 ranked evidence items (3 high-relevance).
Portfolio teams should assess the impact of this approval on market share and pricing strategies for Ciclopirox formulations. The strongest clinical anchor is Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia (ClinicalTrials.gov), sponsor/company relevance (novartis). In Dermatology · Antifungal, 3 regulatory and 2 competitive items passed relevance filtering for Glenmark Pharmaceuticals.
The most relevant competitive pressure comes from FDA Accepts Supplemental Application for TRYNGOLZA Autoinjector (Humanexa Signals) — moderate corpus alignment. Secondary pressure from FDA Orders Azurity Pharmaceuticals to Halt Distribution of Unapproved Compounding Kits. This approval could enhance Glenmark's position in the antifungal market, potentially increasing competition against existing Ciclopirox products.
Regulatory risk is concentrated around FDA AP — CICLOPIROX (SUPPL) (FDA). Entity match (ciclopirox); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The acceptance of this ANDA indicates a successful regulatory pathway for Glenmark, but ongoing monitoring of the market launch and compliance will be essential.
FDA AP — CICLOPIROX (SUPPL)
FDAhigh relevance
Entity match (ciclopirox); Regulatory pathway relevance (nda)
FDA document
View sourceClass 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28
MHRAmedium relevance
Moderate corpus alignment
FDA document
View sourceFDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View sourceStudy to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View sourceOpen-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (P
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View sourceLentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceStudy of Voicing My CHOiCES as Tool for Advanced Care Planning in Young Adults With Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceDepartment of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceEffect of Foot Massage on Pain and Analgesic Consumption in Total Knee Prosthesis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceEffects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceFDA Accepts Supplemental Application for TRYNGOLZA Autoinjector
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Orders Azurity Pharmaceuticals to Halt Distribution of Unapproved Compounding Kits
Humanexa Signalsmedium relevance
Moderate corpus alignment
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceTargeting lymphotoxin β receptor: from mechanism to precision therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceRepurposing nitazoxanide as a novel ferroptosis inducer for triple-negative breast cancer via dual disruption of iron homeostasis and the β-catenin/GPX4 axis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe FDA's acceptance of Glenmark's ANDA for Ciclopirox signifies a potential shift in the competitive landscape of the antifungal market. This approval may lead to increased competition, impacting pricing and market share for existing Ciclopirox products.
Glenmark's entry into the market with Ciclopirox could disrupt current pricing strategies and market shares of existing competitors, potentially affecting revenue streams.
The acceptance of this ANDA indicates a successful regulatory pathway for Glenmark, but ongoing monitoring of the market launch and compliance will be essential.
Monitor the timeline for market launch and any potential competitive responses from other manufacturers.
Track for follow-up milestones; no immediate action required.